000874734 001__ 874734
000874734 005__ 20210130004750.0
000874734 0247_ $$2doi$$a10.1093/brain/awaa019
000874734 0247_ $$2ISSN$$a0006-8950
000874734 0247_ $$2ISSN$$a1460-2156
000874734 0247_ $$2Handle$$a2128/24617
000874734 0247_ $$2altmetric$$aaltmetric:76072032
000874734 0247_ $$2pmid$$apmid:32057084
000874734 0247_ $$2WOS$$aWOS:000522641900028
000874734 037__ $$aFZJ-2020-01643
000874734 082__ $$a610
000874734 1001_ $$0P:(DE-HGF)0$$aRuppert, Marina C$$b0
000874734 245__ $$aNetwork degeneration in Parkinson’s disease: multimodal imaging of nigro-striato-cortical dysfunction
000874734 260__ $$aOxford$$bOxford Univ. Press$$c2020
000874734 3367_ $$2DRIVER$$aarticle
000874734 3367_ $$2DataCite$$aOutput Types/Journal article
000874734 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1585558504_6151
000874734 3367_ $$2BibTeX$$aARTICLE
000874734 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000874734 3367_ $$00$$2EndNote$$aJournal Article
000874734 520__ $$aThe spreading hypothesis of neurodegeneration assumes an expansion of neural pathologies along existing neural pathways. Multimodal neuroimaging studies have demonstrated distinct topographic patterns of cerebral pathologies in neurodegeneration. For Parkinson’s disease the hypothesis so far rests largely on histopathological evidence of α-synuclein spreading in a characteristic pattern and progressive nigrostriatal dopamine depletion. Functional consequences of nigrostriatal dysfunction on cortical activity remain to be elucidated. Our goal was to investigate multimodal imaging correlates of degenerative processes in Parkinson’s disease by assessing dopamine depletion and its potential effect on striatocortical connectivity networks and cortical metabolism in relation to parkinsonian symptoms. We combined 18F-DOPA-PET, 18F-fluorodeoxyglucose (FDG)-PET and resting state functional MRI to multimodally characterize network alterations in Parkinson’s disease. Forty-two patients with mild-to-moderate stage Parkinson’s disease and 14 age-matched healthy control subjects underwent a multimodal imaging protocol and comprehensive clinical examination. A voxel-wise group comparison of 18F-DOPA uptake identified the exact location and extent of putaminal dopamine depletion in patients. Resulting clusters were defined as seeds for a seed-to-voxel functional connectivity analysis. 18F-FDG metabolism was compared between groups at a whole-brain level and uptake values were extracted from regions with reduced putaminal connectivity. To unravel associations between dopaminergic activity, striatocortical connectivity, glucose metabolism and symptom severity, correlations between normalized uptake values, seed-to-cluster β-values and clinical parameters were tested while controlling for age and dopaminergic medication. Aside from cortical hypometabolism, 18F-FDG-PET data for the first time revealed a hypometabolic midbrain cluster in patients with Parkinson’s disease that comprised caudal parts of the bilateral substantia nigra pars compacta. Putaminal dopamine synthesis capacity was significantly reduced in the bilateral posterior putamen and correlated with ipsilateral nigral 18F-FDG uptake. Resting state functional MRI data indicated significantly reduced functional connectivity between the dopamine depleted putaminal seed and cortical areas primarily belonging to the sensorimotor network in patients with Parkinson’s disease. In the inferior parietal cortex, hypoconnectivity in patients was significantly correlated with lower metabolism (left P = 0.021, right P = 0.018). Of note, unilateral network alterations quantified with different modalities corresponded with contralateral motor impairments. In conclusion, our results support the hypothesis that degeneration of nigrostriatal fibres functionally impairs distinct striatocortical connections, disturbing the efficient interplay between motor processing areas and impairing motor control in patients with Parkinson’s disease. The present study is the first to reveal trimodal evidence for network-dependent degeneration in Parkinson’s disease by outlining the impact of functional nigrostriatal pathway impairment on striatocortical functional connectivity networks and cortical metabolism.
000874734 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000874734 588__ $$aDataset connected to CrossRef
000874734 7001_ $$0P:(DE-HGF)0$$aGreuel, Andrea$$b1
000874734 7001_ $$0P:(DE-HGF)0$$aTahmasian, Masoud$$b2
000874734 7001_ $$0P:(DE-HGF)0$$aSchwartz, Frank$$b3
000874734 7001_ $$0P:(DE-HGF)0$$aStürmer, Sophie$$b4
000874734 7001_ $$0P:(DE-HGF)0$$aMaier, Franziska$$b5
000874734 7001_ $$0P:(DE-HGF)0$$aHammes, Jochen$$b6
000874734 7001_ $$0P:(DE-HGF)0$$aTittgemeyer, Marc$$b7
000874734 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b8
000874734 7001_ $$0P:(DE-HGF)0$$avan Eimeren, Thilo$$b9
000874734 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b10$$ufzj
000874734 7001_ $$0P:(DE-HGF)0$$aEggers, Carsten$$b11$$eCorresponding author
000874734 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awaa019$$gVol. 143, no. 3, p. 944 - 959$$n3$$p944 - 959$$tBrain$$v143$$x1460-2156$$y2020
000874734 8564_ $$uhttps://juser.fz-juelich.de/record/874734/files/Ruppert_2020_Brain_Network%20degeneration%20in%20Parkinson%27s%20disease.pdf$$yOpenAccess
000874734 8564_ $$uhttps://juser.fz-juelich.de/record/874734/files/Ruppert_2020_Brain_Network%20degeneration%20in%20Parkinson%27s%20disease.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000874734 909CO $$ooai:juser.fz-juelich.de:874734$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000874734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b9$$kFZJ
000874734 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a INM-3$$b9
000874734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b10$$kFZJ
000874734 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000874734 9141_ $$y2020
000874734 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000874734 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000874734 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000874734 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2017
000874734 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBRAIN : 2017
000874734 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000874734 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000874734 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000874734 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000874734 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000874734 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000874734 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000874734 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000874734 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000874734 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000874734 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000874734 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000874734 920__ $$lyes
000874734 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000874734 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000874734 980__ $$ajournal
000874734 980__ $$aVDB
000874734 980__ $$aUNRESTRICTED
000874734 980__ $$aI:(DE-Juel1)INM-3-20090406
000874734 980__ $$aI:(DE-Juel1)INM-2-20090406
000874734 9801_ $$aFullTexts